ArticleFrontiers in oncology2025
Toripalimab plus gemcitabine and cisplatin induction chemotherapy in locoregionally advanced nasopharyngeal carcinoma: a retrospective study.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Therapeutic Innovations in Nasopharyngeal Carcinoma: Current Strategies and Emerging Perspectives.Life (Basel, Switzerland) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To explore the efficacy and safety of toripalimab combined with gemcitabine and cisplatin (GP) induction chemotherapy and sequential concurrent chemoradiotherapy in LANPC treatment. Methods: This was a retrospective analysis of 105 patients with LANPC from December 2019 to December 2022. In total, 50 patients received two or three cycles of GP induction chemotherapy and 55 patients received toripalimab plus GP. Toripalimab (240 mg) was given intravenously on the first day of each cycle of induction chemotherapy. All patients received radiotherapy or concurrent chemoradiotherapy with cisplatin. Results: After induction therapy, 17 (30.9%) patients in the GP plus toripalimab group and 6 (12.0%) in the GP alone group achieved complete response (CR) (p=0.019). After a median follow-up of 38.6 months, 16.0% (8/50) of the patients in the GP group and 3.6% (2/55) of the patients in the toripalimab plus GP group experienced recurrence or metastasis. There were 2 deaths in the GP group and no deaths in the toripalimab plus GP group. The 2-year event-free survival (EFS) rate was higher in the toripalimab plus GP group than in the GP group (98.1% vs. 85.4% (HR, 0.28; 95% confidence interval [CI], 0.08-0.97; p=0.024)). The 2-year overall survival, locoregional relapse-free survival and distant metastasis-free survival rates for toripalimab plus GP vs. GP alone were 100.0% vs. 100.0% (p=1.00), 98.1% vs. 89.5% (p=0.086), and 100.0% vs. 95.9% (p=0.15), respectively. Grade 3-4 adverse events (AEs) occurred in 26 (47.3%) and 29 (58.0%) patients in the toripalimab plus GP and GP alone arms, respectively. The most common grade 3-4 AEs were neutropenia (20 [36.4%] vs. 21 [42.0%]), leukopenia (18 [32.7%] vs. 17 [34.0%]), and vomiting (15 [27.3%] vs. 12 [24.0%]) in the toripalimab plus GP arm compared with the GP alone arm. Immune-related AEs of grade 3-4 occurred in three (5.5%) patients in the toripalimab plus GP arm. Conclusions: The addition of toripalimab to GP induction chemotherapy significantly improves EFS without increasing toxicity in LANPC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.